Methodological issues in current antipsychotic drug trials.
about
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesCost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophreniaChanges in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacologyRelapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trialEffects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.Antipsychotic Maintenance Treatment: Time to Rethink?Unanswered questions in schizophrenia clinical trialsTime to discontinuation of antipsychotic drugs in a schizophrenia cohort: influence of current treatment strategies.Past and present progress in the pharmacologic treatment of schizophrenia.Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.Second-generation antipsychotics for schizophrenia: can we resolve the conflict?QTc Prolongation in Patients Acutely Admitted to Hospital for Psychosis and Treated with Second Generation Antipsychotics.Influence of different second generation antipsychotics on the QTc interval: A pragmatic study.Clinical trial design in non-invasive brain stimulation psychiatric research.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine.Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.Modelling and simulation of placebo effect: application to drug development in schizophrenia.Patient-reported outcome measures: are they patient-generated, patient-centred or patient-valued?Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness.Pharmacological approaches to the management of schizophrenia: 10 years on.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?Trajectories of change in depression severity during treatment with antidepressants.Generalizability of clinical trial results for generalized anxiety disorder to community samples.The interrelation of needs and quality of life in first-episode schizophrenia.Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
P2860
Q26863435-75EF8B6A-AF66-42F3-A9E2-F33114D7624CQ30590794-B2ABA6BC-0EC7-481B-B68C-CB3380AE0FBBQ30792325-2577229D-91DB-41D7-AFB0-FEF4A92AE960Q31029201-B9235835-24D8-460F-976B-5DEEFB95F1C2Q33538059-4BC28557-6FFD-46F5-A18C-E415D1EEA6CCQ33818732-EB578D25-FB68-4C52-884E-AE4CBCB49714Q34007868-3460D5D4-E295-4021-9CE9-CBE8D07C8F0FQ34266750-0F2762D9-6FB5-41E4-85C0-1D199B1E465DQ34488215-42CE73F0-9807-4F86-9415-B703679B7EDBQ34587166-461E38CA-F73E-420A-AFBC-A50667F510E0Q34642820-7E32103D-20EB-42C8-B0F0-AA5CACBF20D5Q34726953-B6AEE928-F37F-4525-AF3A-D41379D84E1AQ35002529-D9C28884-8F0A-4627-AFA6-98D4D2DCFF20Q37428125-DAB414F6-E311-4AEA-9019-61EDA8CE912AQ37486960-969B0F20-4931-42BB-8E95-9D50CAF4E668Q37532019-64A787F3-75FD-49C0-832E-A0D25FD1A4CEQ37871523-5FDB840D-E680-427E-9D35-3F76C6A84086Q37886138-1802038F-6D8E-47A3-9A28-925DCC265ECDQ37998840-D3955532-0FA1-4D15-A161-D50BF3F3D942Q38070179-6B6C32D8-E4C6-4114-BDD8-61F1A324B460Q38073697-D8A8B397-3438-4C66-A7B2-C3F7512E9FEBQ38074478-DDDEB606-7F77-471D-97DD-2EF36F1C21AFQ38076126-61D01418-5E3F-4DBD-8FF2-CACEE77060B4Q38101540-9CEA3777-5860-45B0-8EAD-502827E4331AQ38676860-BCFB60BD-1089-466E-BCB8-965CC5206BAEQ40055789-65EAFF5E-A87F-49AA-B748-429C61F94F57Q43253362-12CF3842-97E8-46CD-8B82-B91E8FA0CE54Q44740214-92424731-7FC1-4A5E-B3AA-6CFDE9222042Q48537147-9F4EC46D-27ED-48E6-904B-13B0E96FA581Q55425101-3D54EC6C-CE6C-4B9B-B3B0-1F3209D00E70
P2860
Methodological issues in current antipsychotic drug trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Methodological issues in current antipsychotic drug trials.
@ast
Methodological issues in current antipsychotic drug trials.
@en
Methodological issues in current antipsychotic drug trials.
@nl
type
label
Methodological issues in current antipsychotic drug trials.
@ast
Methodological issues in current antipsychotic drug trials.
@en
Methodological issues in current antipsychotic drug trials.
@nl
prefLabel
Methodological issues in current antipsychotic drug trials.
@ast
Methodological issues in current antipsychotic drug trials.
@en
Methodological issues in current antipsychotic drug trials.
@nl
P2093
P2860
P356
P1476
Methodological issues in current antipsychotic drug trials.
@en
P2093
Johannes Hamann
John M Kane
Stefan Leucht
Stephan Heres
P2860
P304
P356
10.1093/SCHBUL/SBM159
P407
P577
2008-01-29T00:00:00Z